Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02883400 · ClinicalTrials.gov registry record · Phase 4
Spironolactone After Liver Transplant
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02883400 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants.
The verdict
NCT02883400, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
Interventions
- DRUG Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02883400
The ClinicalTrials.gov registry entry for NCT02883400 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spironolactone is the first listed.
NCT02883400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02883400 about?
NCT02883400 is a clinical study titled "Spironolactone After Liver Transplant". To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
What is the current status of trial NCT02883400?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02883400?
The interventions under investigation include: Spironolactone (DRUG).
Who is sponsoring clinical trial NCT02883400?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.